SCHEMBL5338654

SCHEMBL5338654

Cc1cccc2c(O)c(C3c4c(c5cccc(C)c5oc4=O)OC3O)c(=O)oc12

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 3/20 0.38
ADORA3 P0DMS8 3/20 0.37
ADORA1 P30542 2/20 0.37
MCL1 Q07820 1/20 0.36
CNR2 P34972 2/20 0.35
GPR55 Q9Y2T6 2/20 0.35
NQO1 P15559 3/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
CES1 P23141 1/20 0.34
KDM4E B2RXH2 1/20 0.32
PRNP P04156 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
ANTXR2 P58335 1/20 0.32
ADORA2A P29274 1/20 0.32
ELANE P08246 1/20 0.31
PRKDC P78527 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5340558 0.85 GABRA1 (0.34) CNR2GPR55NQO1PRNPRXFP1
SCHEMBL5345493 0.85 NQO1 (0.51) ESR2MCL1CNR2GPR55NQO1
SCHEMBL5337992 0.85 TTR (0.34) NQO1PRNPRXFP1
SCHEMBL5341632 0.84 HIF1A (0.33) GPR55NQO1PRNPRXFP1
SCHEMBL5112371 0.84 ESR2 (0.36) ESR2ADORA3ADORA1MCL1CNR2
SCHEMBL5337618 0.82 ESR2 (0.49) ESR2KDM4E
SCHEMBL5338619 0.82 PKLR (0.47) ESR2MCL1KDM4E
SCHEMBL5110816 0.82 ESR2 (0.34) ESR2ADORA3ADORA1MCL1CNR2
SCHEMBL5343002 0.80 CSNK2A2 (0.38) ESR2MCL1KDM4E
SCHEMBL5336515 0.77 ESR2 (0.36) ESR2ADORA3ADORA1NQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US claimed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US claimed
EP-1648901-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP claimed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO claimed
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action LTC4S, CYP11B2, CYP11B1 ESR2 779/4885ADORA3 925/4885ADORA1 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.